Bellevue Asset Management AG: 15 Jahre Bellevue Medtech & Services Fund

Bellevue Asset Management AG / Schlagwort(e): Fund

15 Jahre Bellevue Medtech & Services Fund – an investment in investment investments

07.10.2024 / 07:00 CET/CEST

Medienmitteilung vom 7. October 2024

15 Jahre Bellevue Medtech & Services Fund – an investment in investment investments

Since 15 years, the Bellevue Medtech & Services Fund of Bellevue Asset Management has been established on the foundation combination with stabilization and diversification in a dynamic sector of medical technology and health services. The Fund was able to launch the Gesamtmarkt event in 2009. As exciting as the venture is, it is not that the next generation of AI technology and disruptive innovation is robbing the industry, the prosperity is being marketed for 15 years.

The Medtech-&-Services sector, the common healthcare industry that has developed the medical sector, has developed a stable and best Wachstumstreiber in healthcare over the past 15 years. With a continuous non-stop lifestyle and innovative products, this sector can be an overwhelmingly beautiful destination. If the profit in the corporate market is greater than 6% per year, then the bet in the Medtech-&-Services sector is 12%. This robust entity is reflected in the performance of the Bellevue Medtech & Services Fund (ISIN B-EUR LU0415391431), during its launch in 2009 a cumulative Wertsteigerung of 471.2% was achieved, an annual interest of 12.3% on the interest (as of 30.09.2009). 2024). This year the assets have increased by 325 million euros. at EUR 1.55 Mr. quick paint job. Since the Fund was managed by Stefan Blum and Marcel Fritsch.

From classic medical technology to digital evolution

“I have been describing the sector as a deutsch diversifizierter and technologically advanced for 15 years. When the focus is on classic medical technology, the sector is an extended spectrum, a digital digital healthcare and service, which is becoming more revolutionary through energy intelligence and data-distributed technology, according to Stefan Blum. “The sector has never become more robust, the market can achieve a higher level of innovative products and a more robust product after good service.” “I am having a turbulent start to 2008’s financial crisis. The companies investing in Forschung & Entwicklung, major brands that implant defibrillators, are one. But it is a large Erholung. The companies are investing massively in market-based medical products with beispielsweise robot-assisted surgery. It is a billion-dollar market that Marcel Fritsch calls the rasante Entwicklung.

A new innovation scale is the best choice

The sector is a new breed of Wachstums. Technological innovations ensure that the brands are the transcatheter herzklappersatz and the continuous glucose monitoring. This range is new in the Medizintechnik-Blockbuster-Markten, and the Herzkklapmarkt will have a volume of more than USD 16 billion in 2028. erreichen. The beach is in the market for CGM sensors, the continuous glucose monitoring and comprehensive diabetes management could be better. Here is a market sale at USD 20B. inner life for fun years.

A separate factor for the use of the sectors is the development of generative AI (GenAI), while major robotic surgery is more profitable. Unternehmen who can achieve intuitive surgical procedures with AI-based robot technology, an operation preziser and confident in machining. The development of new AI surgery systems with 5 new technologies, a minimally invasive effect, is being further optimized.

The Gesundheitsdienstleister uses the potential of generative intelligent intelligence. UnitedHealth offers a precaution here. As a vertical integrator of medical solutions, medical management and data management, the Unternehmen has invested over the years in Big Data solutions and the set of GenAI, a process-leadership and an information provider of shapes, aber one of the clinical qualifications it has been optimized. The efficiency and costs can be beneficial for the positive margins and the legal efficiency of the internal systems.

Stefan Blum jumps on GenAI’s opportunity with the next step: «GenAI has the opportunity to bring the healthcare industry to a new level of efficiency. Davon benefits from patients as partners and investors.”

View for the Monate Kommenden – Rückenwind stops een

The latest medical care is a positive development in 2024 with a strong recovery of surgical treatment, until it can no longer be performed for years. The preissetzungsmacht no longer lasts an intelligent institution and the Margen will list the excessive debt burden that allows the further translation of the lovely steepen. Krankenhäuser makes profits on high investment volumes, higher prices and moderate personal costs. If the US portfolio management team has built a solid view of the financial sector with one of the best investment objectives, the lender can better focus on Stehen’s investment funds. The political risks may be relatively small and now we cannot deal with the damage we have done to politics. It is a fact that the US-Wahlen has no longer brought clarity to either chamber in November 2024. For an investment in the Bellevue Medtech & Services (Lux) Fund, the Leitzinssenkungen is informed about an American economy, attractive investment levels, the new positioning of investors from the outperformer of the letzten-monate that offers the high quality of trading.

More information: www.bellevue.ch/15-jahre-medtech

Please contact us
Bellevue Asset Management AG, Seestrasse 16, 8700 Kusnacht/Zürich,
Tanja Chicherio, tel. +41 44 267 67 07, [email protected], www.bellevue.ch

Bellevue – Excellence in Specialized Investments
Bellevue is a specialist asset manager with core competencies in healthcare strategies, alternative and traditional investment strategies, informed by the SIX Swiss Exchange. Gegründet 1993, Bellevue generiert als Haus der Anlageideen with beef 90 Mitarbeitenden attractive Anlageperformances and also more information for their actions. As of June 30, 2024, Bellevue Kundenvermögen in Höhe was worth CHF 6.7 billion.

Disclaimer: This document is not for the Verteilung een or de Verwendung door Personen or Einheiten bestimmt, de Staatsangehörigkeit or de Wohn-oder Geschäftssitz a einem Ort, Staat, Land or Gerichtskreis has, in a single Verteilung, Veröffentlichung, Bereitstellung or Verwendung gegen Gesetze or other Bestimmungen verstösst. The information and data contained in the previous documents will require a Purchase or Verkaufsangebot or an Aufforderung zur Zeichnung van Wertpapers or Financial Instruments in the fall. The information contained in the previous document, the contents and the processing of information about the publication of the publication can be continued for a certain period of time. The direction and the entire content of the inhalation cannot have any influence. This information is not based on the specific and non-financial investments, nor on the financial or regulatory low or individual business capabilities of an entrepreneur. This document cannot be used if an unhung is used. Interesting investors may be concerned with the occupational separation they entail. The documents contained herein were offered without warranty or guarantee of sale, which contained the information in full and was fully covered by the company’s best employees. When you take a risk, you experience the world’s problems and problem solving, connected. If the Fremdwährungen best deal with the risks, then the Fremdwährung gegenüber der Referenzährung des Anlegers en Wert verliert. In this document, not all risk towers in the future are included in the paper or in the financing instruments. Historical trading and financial markets do not provide any guarantee or indicator for washing and buying large amounts. Those at the Zeichnung or the Rücknahme are cases of Kommissionen and Gebühren that do not end up in the Performance activities. Commissions and costs will be charged overnight on the performance aus. Financing transactions are now underway after a thorough study of the jewels and are now based on the jewelery’s basis for the prospects and years ahead. Halbjahresberichtes generous. The Bellevue Funds (Lux) SICAV is established in Switzerland with open access and business opportunities. Traveler in Switzerland: Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne. Zahlstelle in der Schweiz: DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, Postfach, CH-8022 Zurich. The Bellevue Funds (Lux) SICAV is legally available in Austria. Zahl- en Informationsstelle: Zeidler Legal Process Outsourcing Limited, 19-22 Lower Baggot Street, Dublin 2, D02 X658, Ireland. Die Bellevue Funds (Lux) SICAV is incorporated in Germany and has a rights right. Information provider: Zeidler Legal Process Outsourcing Limited, SouthPoint, Herbert House, Harmony Row, Grand Canal Dock, Dublin 2, Ireland. The Bellevue Funds (Lux) SICAV is registered in the register of the CNMV for Austrian, Spanish-owned Kollektivanlagen, under registration number 938, logged in. Delivery: atl Capital, Calle de Montalbán 9, ES-28014 Madrid. Prospekt, Key Investor Information Document (PRIIP-KIID), Articles of Association of the Luxembourg Fund and the Annual Report of the Luxembourg Fund, on the right, they can be provided free of charge and that both of them are provided with Zahl- en Informationsstellen at Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht was delivered. Make sure that you receive a benefit from the trust funds in one of the other countries and focus on the seat of the losers.

End of the Medienmitteilungen